Switch data back Chiesi/Protalix long-acting Fabry drugChiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, Share XSwitch data back Chiesi/Protalix long-acting Fabry drughttps://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/
Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase Share XChiesi’s flagship Fabry drug heads for FDA verdict in early 2021https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/
Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
